Latin America

  • Caplin Point: What should investors do

    Caplin Point Laboratories has shown remarkable progress and continues to be on a growth path. Earlier, in July 2022, we recommended that investors accumulate the stock, and the stock, after returning 90 per cent, is still poised for further growth. At 18 times one-year forward earnings, it is at a premium to its historical valuation range of 16 times. But considering earnings growth visibility and modest valuations compared to bigger players (averaging 23 times one-year forward earnings), we reiterate the accumulate call on Caplin Point.

    stock options April 22, 2024